arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Praxis Precision Medicines, Inc.

PRAX

$360.80 ▼ -8.61 (-2.33%) at close

8 Visible periods

22 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Praxis Precision Medicines, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $8.1B

Dividend Yield —

Revenue Growth N/M

Op. Margin —

ROIC -37.2% ↘

FCF / Share $-11.07 ↘

Trailing P/E —

Price / Book 10.4x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

8-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$0.00

↓ -100.0% —

Net Income Profit after all expenses

$-303.27M

↓ -65.9% —

FCF / Share Free cash flow per share

$-11.07

↓ -50.4% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↑

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Revenue Growth YoY (%)	N/M	249.5% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+3019%)	—	—	—	—	—	—
EPS Growth YoY (%)	-32.0% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	45.4% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	73.2% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-17.9% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	49.9% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—	—
Net Income Growth YoY (%)	-65.9% Weak ↓ Weak Declining Year-over-year change in net income	-48.3% Weak ↑ Weak Improving Year-over-year change in net income	42.4% Excellent ↑ Excellent Improving Year-over-year change in net income	-28.1% Weak ↑ Weak Improving Year-over-year change in net income	-170.2% Weak Weak Year-over-year change in net income	-74.1% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	-50.4% Weak ↓ Weak Declining Year-over-year change in free cash flow	56.4% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	72.1% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	-36.1% Weak Weak Year-over-year change in free cash flow	49.7% Excellent Excellent Year-over-year change in free cash flow	—	—	—

💰 Are margins durable? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Effective Tax Rate (%) (%)	-0.2% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—	—	0.0% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.2% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—
FCF / Net Income (x)	0.82x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.72x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.90x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.87x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.75x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.85x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.94x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Return on Invested Capital (%)	-37.2% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-35.5% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-115.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-161.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-56.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	50.3% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	44.1% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-34.8% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-41.4% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-143.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-186.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-57.2% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-20.4% Weak Weak Operating profit relative to total assets Optimal: > 10%	-75.0% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-34.5% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-330%)	-41.0% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-374%)	-142.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1047%)	-203.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1457%)	-56.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-476%)	50.2% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+234%)	43.8% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+192%)	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Net Debt (USD)	$-357.33M	$-215.37M	$-81.30M	$-61.62M	$-138.70M	$-296.61M	$-44.81M	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Revenue per Share (USD)	$0.00	$0.48	$0.37	$0.00	—	—	—	—
Basic EPS, GAAP (USD)	$-13.48	$-10.21	$-18.69	$-69.65	$-59.07	$-117.84	—	—
Free Cash Flow per Share (USD)	$-11.07	$-7.36	$-16.86	$-60.36	$-44.36	$-88.15	—	—
Book Value per Share (USD)	$34.85	$22.93	$9.87	$31.94	$97.94	$-48.29	$-748.83	—
Tangible Book Value per Share (USD)	$34.85	$22.93	$9.87	$31.94	$97.94	$-48.29	$-748.83	—
Basic Weighted Avg Shares (shares)	22.50M	17.91M	6.59M	3.07M	2.83M	596,975	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Working Capital (USD)	$551.14M	$366.82M	$69.13M	$76.50M	$248.97M	$286.61M	$38.68M	—
Total Equity (USD)	$878.14M	$445.45M	$86.76M	$105.16M	$295.92M	$-123.26M	$-81.01M	$-41.04M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Sales/Revenue/Turnover (USD)	$0.00	$8.55M	$2.45M	$0.00	—	—	—	—
Depreciation Expense (USD)	$140.00K	$358.00K	$432.00K	$419.00K	$182.00K	$50.00K	$37.00K	—
Net Income, GAAP (USD)	$-303.27M	$-182.82M	$-123.28M	$-214.03M	$-167.06M	$-61.82M	$-35.51M	—
Operating Cash Flow (USD)	$-249.07M	$-131.76M	$-111.14M	$-185.04M	$-124.55M	$-52.62M	$-33.42M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 8 years · 29 quarters

Praxis Precision Medicines, Inc.

Analytical Summary

8-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare PRAX with peers